{"name":"Tenaya Therapeutics","slug":"tenaya","ticker":"TNYA","exchange":"NASDAQ","domain":"tenayatherapeutics.com","description":"Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.","hq":"South San Francisco, CA","founded":0,"employees":"70","ceo":"Faraz Ali","sector":"Gene Therapy / Cardiovascular","stockPrice":0.96,"stockChange":0,"stockChangePercent":0,"marketCap":"$207M","metrics":{"revenue":225000,"revenueGrowth":0,"grossMargin":100,"rdSpend":68607000,"netIncome":-90597000,"cash":100547000,"dividendYield":0,"peRatio":-2.3,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"TNY-A007 patent cliff ($0.00 at risk)","drug":"TNY-A007","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"TNY-A008 patent cliff ($0.00 at risk)","drug":"TNY-A008","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Tenaya Therapeutics Announces FDA Clearance of IND for TNY-A007","summary":"Tenaya Therapeutics announced that the FDA has cleared the Investigational New Drug (IND) application for TNY-A007, a gene therapy candidate for the treatment of dilated cardiomyopathy.","drugName":"TNY-A007","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Tenaya Therapeutics Reports Third Quarter 2023 Financial Results","summary":"Tenaya Therapeutics reported its financial results for the third quarter of 2023, with a net loss of $13.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-08-15","type":"deal","headline":"Tenaya Therapeutics Announces Collaboration with University of California, San Francisco","summary":"Tenaya Therapeutics announced a collaboration with the University of California, San Francisco to develop gene therapies for cardiovascular diseases.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-14","type":"deal","source":"simplywall.st","summary":"How TN-301 Progress And Alnylam Deal At Tenaya Therapeutics (TNYA) Has Changed Its Investment Story - simplywall.st","headline":"How TN-301 Progress And Alnylam Deal At Tenaya Therapeutics (TNYA) Has Changed Its Investment Story","sentiment":"neutral"},{"date":"2026-03-11","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPQ3dybnZpeERvWXVIQkh4LUNYQzd1WFp6Q3lXUnJkUEg0bjcweE4yNWI3SWU0NkdEbWREN0pPN1FVSV8wYXFTQk1Jc0dkcm13T0xMSGFRaVpwQ1M5Uko3bG9HOGNWZ2s3dURONkFJeEJ2VkRjSmJqaGQxMF9GV19MazRxNENHc0RMVUFxZVc2N0NjeUNELTFyWEVjVFVHcVlSX1pTQ3NEOE1mamRsRFBBTExB?oc=5","date":"2026-03-06","type":"deal","source":"The Pharma Letter","summary":"Tenaya Therapeutics inks $1 billion-plus research deal with Alnylam - The Pharma Letter","headline":"Tenaya Therapeutics inks $1 billion-plus research deal with Alnylam","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPdHBFSXlqS0s0MFRYR19pem5zSGN4LUJaZy1vWlhvOVVWSTJ1U0tSbGU2UW1ZekVwXzctbVdPUGtaN3h4TlNjX1pxcTlhSWlYZFloTHFqRU9sU05UdjdXb3B3T2JZdDVHbHVVU3U2YjYxRUN6Mkt0S3VjNldhbXVBNV9MdzlYNTRQVU9zQVBTSTdmck1XVkJqNFhMSnhHcjlKaVU3SjZxbEJRaFQyaWhpTEpPbTJlTzU0eklKWDR3QQ?oc=5","date":"2026-03-05","type":"pipeline","source":"Stock Titan","summary":"Biotech duo chases new heart disease genes in $1.13B research pact - Stock Titan","headline":"Biotech duo chases new heart disease genes in $1.13B research pact","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wJBVV95cUxNQTVEVnBnYWdmTUlQTVZQVFdhSXppY0t4dlR4emx0d1gyNU95WVVlcFZpcjdJMGlhQmI1WFZqLVJ3SzJIak5wMlFLMEpLMVlGTFBpWjlNaGZPMHFCVmw5QlFuUGtnWTZ3V1lCVmRRdmVJNjZkbFo4M2w3V0lNMm5uVkVhSmVYZ290ejQ3YUdReVh2czVlUmVHLVJuWGE1dWJoekxTTmZFUlluakgyTElSNGRGbG55dFJBNkhudjJFdkxIZGZOMmtRdGV1Y0VtVEdCQ29yMGkxMjUxbmdwSWFQSnBzajluaXRZMEpEaDU5WUNkbENHT2FhN0RyeDE4Q3JSRHYxbERzMFhBZnBCWEo4ZVBYQy1fZXZ1RTR1VE8wTFJBZ0ZFTHdCZ0NjY251UmVYbEFsVjFXTHQ2ZE5VTGZJRlhNNE82OXN5cGxHSzBfQ2FkRGwzTGl1RjlxaHh1QW8?oc=5","date":"2026-03-05","type":"deal","source":"GlobeNewswire","summary":"Tenaya Therapeutics Enters into Research Collaboration with - GlobeNewswire","headline":"Tenaya Therapeutics Enters into Research Collaboration with","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPOHc2cFhVRzYxd3J1MEJoTGNnQjVNMnlJNzdVOTBUVmFaRUJMR1g1eWtDQVRhSWt6UFVpekFsUnJtMElzV0ltYTNjaWhRYjQxQnYxRjdsUU1OSTFEdi1XOGgtRkx5MHM2ektYc3RmZHczQkM3Z0VKS1pzbXMydHRUTXZKTmdZWkd0TzVrWDZGYXFKQjlMeW4ybWotLS1wdmxjSERUYTk1cGJSLUtSQWhPVw?oc=5","date":"2026-03-05","type":"deal","source":"Benzinga","summary":"Tenaya Therapeutics Stock Jumps After New Alnylam Deal - Benzinga","headline":"Tenaya Therapeutics Stock Jumps After New Alnylam Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxPbE5ralNtVk1XVk5UdElCd2U5MGNhcEJQRGFKRGFTUHFRRmd5RllvNENaWVFNWHVsQzQ2X3FUbE9EYW1rVl9EV1Fhcjl4WG5VQUdJT2MyNHR5aFIyVnVUZUpDa2FBM2ZUTHZsb3ZpLVRJTmlJWUg0ZWYtdFc2OHBpSE1WVU9wRjQ?oc=5","date":"2026-03-05","type":"pipeline","source":"Seeking Alpha","summary":"Alnylam’s research pact worth up to $1.1B sends Tenaya higher - Seeking Alpha","headline":"Alnylam’s research pact worth up to $1.1B sends Tenaya higher","sentiment":"neutral"},{"date":"2026-03-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxNbDlQQ1cwcE05UFc3Tmh5MzNfbDhDOF9aaE1lN0tBcU92eExmWk1GZHRQbkZZSGxPMWhzZzJ2ZGJ2alFQcVhRTHUwRUtWWmN1TnNSYmVNNDFqR2RObmktNmppOVRYd0RBR0FIVVZfRmVabi0yLVhNQW9lYkVXOFVlNmxNUXFTUV9sTjFTZVZ3NzJMRXdld0JEeWQ5S3dCd2tG?oc=5","date":"2025-12-15","type":"pipeline","source":"The Pharma Letter","summary":"Tenaya fundraising follows resolution of clinical hold - The Pharma Letter","headline":"Tenaya fundraising follows resolution of clinical hold","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxQeGNFMFRPczQ2ZWw2UGh2OWxJTWxYZXlDcWtvcjV3MWI1WGxHWEVOQmdSd2VCYWRRLW11TFJ4ZXFEQzQ0dlBBd2ZoajdhaUNjaFh6YzVabjMyOHU1bllsTlRrSzdjZGpPQW85LWw5OU14ZFlNWlZTZTFteU5NbldSVFdlaWxZWkx1Ujk0NGdIV2gxREp6MzhaRm9wZUpoenRQcEM2MU9IY1kwODBkZHh6UkszT0JXZnluZ2lXTDM3UElrTmhPWkQtYmNGTGlBWkkwb1N4dGYwTl8zMERx?oc=5","date":"2025-11-07","type":"regulatory","source":"Reuters","summary":"US FDA places clinical hold on Tenaya gene therapy trial for rare heart disease - Reuters","headline":"US FDA places clinical hold on Tenaya gene therapy trial for rare heart disease","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-21","type":"pipeline","source":"simplywall.st","summary":"Will Tenaya Therapeutics (NASDAQ:TNYA) Spend Its Cash Wisely? - simplywall.st","headline":"Will Tenaya Therapeutics (NASDAQ:TNYA) Spend Its Cash Wisely?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPM09MNjFhbEZjNlAtWWtwSjdsektqaS1KMFpnVnZ2WkZ3NEFlSEI0aWZYWmtUeHoxdkRWamc4bWxmanVtOFY0NFR2QnNMdklXb09TRERtV1JUSTV1Qzdia1hGU016T3lUMFBsZFdxM3YzenRlVnE1eExURG1hd3BzRVpnLUdFVURvRVpPOVRWQ21Ba2w5ckFqZmhLdm55SVRTeGJuS3BFZEh0VWFEU3d4VGxEbw?oc=5","date":"2025-02-03","type":"trial","source":"Stock Titan","summary":"Major Funding Breakthrough: Rare Heart Disease Gene Therapy Trial Gets $8M Boost - Stock Titan","headline":"Major Funding Breakthrough: Rare Heart Disease Gene Therapy Trial Gets $8M Boost","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE94aXZ3TF9reUtrMmdmVFlnTURrTlkzUHNMQ0NfOTRBTHRwRm5KVy0td3NpS0wxVkp4LXQxUVVBaVQ0aklkR1NlZjhvTGlnb0lO?oc=5","date":"2024-03-06","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTE1fN2x1ci11Q3VqVDVod2hhTkZDNlBXeXVUQ2N1VGptb0FZdXluRXdOOEJmd2dQb2liUjFXVHZ1OUdQa2QxVGFySVdKRVFDYVFqRXc?oc=5","date":"2021-08-03","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Tenaya Therapeutics, Inc. (TNYA) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"Tenaya Therapeutics, Inc. (TNYA) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"}],"patents":[{"drugName":"TNY-A007","drugSlug":"tny-a007","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0},{"drugName":"TNY-A008","drugSlug":"tny-a008","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Editas Medicine","CRISPR Therapeutics","Verve Therapeutics"],"therapeuticFocus":["Cardiovascular","Gene Therapy"],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":0},{"period":"2024-12-31","value":0},{"period":"2023-12-31","value":0},{"period":"2022-12-31","value":0}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":68607000,"rdSpendHistory":[{"period":"2025-12-31","value":68607000},{"period":"2024-12-31","value":86742000},{"period":"2023-12-31","value":98038000},{"period":"2022-12-31","value":94537000}],"sgaSpend":24724000,"operatingIncome":-93331000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-93331000},{"period":"2024-12-31","value":-115948000},{"period":"2023-12-31","value":-131193000},{"period":"2022-12-31","value":-125621000}],"netIncome":-90597000,"netIncomeHistory":[{"period":"2025-12-31","value":-90597000},{"period":"2024-12-31","value":-111129000},{"period":"2023-12-31","value":-124084000},{"period":"2022-12-31","value":-123665000}],"eps":-1.31,"epsHistory":[{"period":"2024-12-31","value":-1.31},{"period":"2023-12-31","value":-1.68},{"period":"2022-12-31","value":-2.76},{"period":"2021-12-31","value":-4.1}],"cash":100547000,"cashHistory":[{"period":"2025-12-31","value":100547000},{"period":"2024-12-31","value":4323000},{"period":"2023-12-31","value":45681000},{"period":"2022-12-31","value":95272000}],"totalAssets":146921000,"totalLiabilities":23656000,"totalDebt":10830000,"equity":123265000,"operatingCashflow":-68264000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-68264000},{"period":"2024-12-31","value":-90501000},{"period":"2023-12-31","value":-102072000},{"period":"2022-12-31","value":-104424000}],"capex":-618000,"capexHistory":[{"period":"2025-12-31","value":-618000},{"period":"2024-12-31","value":-1025000},{"period":"2023-12-31","value":-1239000},{"period":"2022-12-31","value":-20630000}],"freeCashflow":-68882000,"dividendsPaid":null,"buybacks":0,"employees":70,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":5977000,"ebit":-20775000,"ebitda":-18948000,"period":"2025-12-31","revenue":0,"epsBasic":-0.12,"netIncome":-20175000,"rdExpense":14798000,"epsDiluted":-0.12,"grossProfit":null,"operatingIncome":-20775000},{"sga":5573000,"ebit":-20936000,"ebitda":-19072000,"period":"2025-09-30","revenue":0,"epsBasic":-0.12,"netIncome":-20275000,"rdExpense":15363000,"epsDiluted":-0.12,"grossProfit":null,"operatingIncome":-20936000},{"sga":6712000,"ebit":-24082000,"ebitda":-21998000,"period":"2025-06-30","revenue":0,"epsBasic":-0.14,"netIncome":-23283000,"rdExpense":17370000,"epsDiluted":-0.14,"grossProfit":null,"operatingIncome":-24082000},{"sga":6462000,"ebit":-27538000,"ebitda":-24877000,"period":"2025-03-31","revenue":0,"epsBasic":-0.24,"netIncome":-26864000,"rdExpense":21076000,"epsDiluted":-0.24,"grossProfit":null,"operatingIncome":-27538000},{"sga":5964000,"ebit":-24652000,"ebitda":-22563000,"period":"2024-12-31","revenue":0,"epsBasic":-0.28,"netIncome":-23836000,"rdExpense":18688000,"epsDiluted":-0.28,"grossProfit":null,"operatingIncome":-24652000}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":0.96,"previousClose":0.96,"fiftyTwoWeekHigh":2.35,"fiftyTwoWeekLow":0.36,"fiftyTwoWeekRange":"0.36 - 2.35","fiftyDayAverage":0.77,"twoHundredDayAverage":1.03,"beta":0,"enterpriseValue":137440416,"forwardPE":-2.3,"priceToBook":1.68,"priceToSales":921.23,"enterpriseToRevenue":610.85,"enterpriseToEbitda":-1.75,"pegRatio":0,"ebitda":-78320000,"ebitdaMargin":0,"freeCashflow":-40363248,"operatingCashflow":-64386000,"totalDebt":10117000,"debtToEquity":9.5,"currentRatio":5.75,"returnOnAssets":-38.5,"returnOnEquity":-73.6,"analystRating":"1.3 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":5,"targetMeanPrice":4.2,"targetHighPrice":8,"targetLowPrice":2,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.5,"institutionHeldPercent":51,"sharesOutstanding":216998876,"floatShares":166770146,"sharesShort":27907191,"shortRatio":9.05,"shortPercentOfFloat":12.9,"epsTrailing":-0.44,"epsForward":-0.42,"revenuePerShare":0,"bookValue":0.57,"officers":[{"age":52,"name":"Mr. Faraz  Ali M.B.A.","title":"CEO, Interim Principal Financial Officer & Director"},{"age":58,"name":"Dr. Deepak  Srivastava M.D.","title":"Scientific Founder, Chairman of Scientific Advisory Board & Director"},{"age":57,"name":"Dr. Whittemore G. Tingley M.D., PH.D.","title":"Chief Medical Officer"},{"age":null,"name":"Dr. Eric N. Olson Ph.D.","title":"Scientific Founder & Member of Scientific Advisory Board"},{"age":null,"name":"Dr. Bruce R. Conklin M.D.","title":"Scientific Founder"},{"age":null,"name":"Dr. Saptarsi  Haldar M.D.","title":"Scientific Founder"},{"age":null,"name":"Dr. Sheng  Ding Ph.D.","title":"Scientific Founder"},{"age":null,"name":"Dr. Benoit G. Bruneau Ph.D.","title":"Scientific Founder"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.tenayatherapeutics.com","phone":"650 825 6990"}}